<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
	<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
	<title>DIURETICS</title>
	<meta name='Generator' content='Zim 0.73.1'>
	<style type='text/css'>
		a          { text-decoration: none      }
		a:hover    { text-decoration: underline }
		a:active   { text-decoration: underline }
		strike     { color: grey                }
		u          { text-decoration: none;
					 background-color: yellow   }
		tt         { color: #2e3436;            }
		pre        { color: #2e3436;
					 margin-left: 20px          }
		h1         { text-decoration: underline;
					 color: #4e9a06; margin-bottom: 0 }
		h2         { color: #4e9a06; margin-bottom: 0 }
		h3         { color: #4e9a06; margin-bottom: 0 }
		h4         { color: #4e9a06; margin-bottom: 0 }
		h5         { color: #4e9a06; margin-bottom: 0 }
		p          { margin-top: 0              }
		span.zim-tag {
			color: #ce5c00;
		}
		div.zim-object {
			border-style:solid;
			border-width:1px;
		}
		.checked-box {list-style-image: url(data:image/png;base64,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)}
		.xchecked-box {list-style-image: url(data:image/png;base64,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)}
		.unchecked-box {list-style-image: url(data:image/png;base64,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)}
		.migrated-box {list-style-image: url(data:image/png;base64,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)}
		ul {list-style-image: none}
		/* ul rule needed to reset style for sub-bullets */
	</style>
</head>
<body>

<!-- Header -->
<div class='header'>
	[ <a href='./Pharmacognosy.html'>Prev</a> ]

	[ <span class='insen'>Index</span> ]

	[ <a href='..\22.html'>Next</a> ]
</div>

<hr />

<!-- Wiki content -->

<div class='pages'>
	<div class='heading'>
	<h1>DIURETICS <a name='21:Pharmacology'></a></h1>
	</div>

	<div class='content'>
	
<h1>I.OVERVIEW</h1>

<p>
→ induce ↑ urine flow <br>
<ul style='padding-left: 30pt'>
<li>inhibitors of renal ion transporter</li>
<li>↓ reabsorption of Na+ at different sites in the nephron</li>
</ul>
→ as a result Na+ and other ions <br>
<ul style='padding-left: 30pt'>
<li>Cl- enter the urine in greater than normal amounts along with water</li>
<li>carried passively to maintain osomotic equillibrium</li>
</ul>
→ Diuretics thus<br>
<ul style='padding-left: 30pt'>
<li>↑ the volume of urine </li>
<li>change the pH</li>
<li>ionic composition of the urine and blood</li>
</ul>
→ efficacy of diuretics varies with the ↑ Na+ secretion<br>
<ul style='padding-left: 30pt'>
<li>2% [weak] → potasium-sparing diuretics</li>
<li>20%[potent] → loop diuretics</li>
<li>osmotic diuretics and carbonic anhydrase inhibitors.
<ul>
<li>that prevent water reabsortption , aldosterone antagonist , </li>
</ul></li>
</ul>
<ul>
<li>used to treat abnormal fluid retention (edema)</li>
<li>treating hypertension
<ul>
<li>in which the diuretic ↓ blood volume → ↓ the peripheral resistance → ↓ blood pressure.</li>
</ul></li>
</ul>
</p>

<h1>II.NORMAL REGULATION OF FLUID AND ELECTROLYTES BY THE KIDNEYS.</h1>

<br>

<p>
→ 16-20% of the blood plasma entering the kideny<br>
<ul style='padding-left: 30pt'>
<li>filtrered from the glomerular capillaries into the Bowman capsule</li>
</ul>
[filtrate free of proteins and blood cells]<br>
<ul style='padding-left: 30pt'>
<li>but does contain low-weight molecular components
<ul>
<li>glucose</li>
<li>sodium bicarbonate</li>
<li>amino acids</li>
<li>other organic solutes </li>
<li>electrolytes (Na,K,Cl)</li>
</ul></li>
</ul>
→ kidney regulates the ionic composition and volume of urine <br>
<ul style='padding-left: 30pt'>
<li>active reabsorption/secretion of ions </li>
<li>and/or passive reabsrorption of water at five functional zones of the nephron</li>
</ul>
<div style='padding-left: 90pt'>
1.the proximal convoluted tubule<br>
2.descending loop of Henle <br>
3.ascending loop of Henle<br>
4.distal convoluted tubule<br>
5.collecting tubule and duct
</div>
→ <img src="./Pharmacology/pasted_image.png"><img src="./Pharmacology/pasted_image001.png">
</p>

<h1>III.KIDNEY FUNCTION IN DISEAE</h1>

<br>

<h1>iii.A.Edematous states</h1>

<p>
→ amount of sodium chloride reabsorbed by the kidney tubules is abnormal high<br>
<ul style='padding-left: 30pt'>
<li>leads to retention of water</li>
<li>↑ blood volume</li>
<li>expansion of the extravascular fluid compartment 
<ul>
<li>resulting in edema in tissues</li>
</ul></li>
</ul>
</p>

<h1>iii.A.1.-Heart failure</h1>

<p>
→ ↓ ability of the failing heart to sustain adequate cardiac output<br>
<ul style='padding-left: 30pt'>
<li>cause the kidney to respond as if there were a ↓ in blood volume (hypovolemia)</li>
</ul>
→ kidney<br>
<ul style='padding-left: 30pt'>
<li>retains more salt and water
<ul>
<li>raising blood volume</li>
<li>increasing the amount of blood that is returned to the heart</li>
</ul></li>
</ul>
→ diseased heart<br>
<ul style='padding-left: 30pt'>
<li>cannot ↑ output</li>
<li>↑ vascular volume → edema</li>
</ul>
→ Loop diuretics are commonly used.
</p>

<h1>iii.A.2.-Hepatic ascites</h1>

<p>
→ accumulation of fluid in the abdominal cavity<br>
<ul style='padding-left: 30pt'>
<li>cirrhosis of the liver</li>
</ul>
a.Increased portal blood pressure<br>
→ blood flow in the portal system is blocked in cirrhosis<br>
<ul style='padding-left: 30pt'>
<li>↑ portal blood pressure</li>
</ul>
b.Secondary hyperaldosteronism<br>
→ fluid retention is also promoted by ↑ levels of circulating aldosterone  due to ↓ blood volume<br>
<ul style='padding-left: 30pt'>
<li>↓ ability of the liver to inactivate the steroid hormone and → ↑ Na+ and water reabsorption
<ul>
<li>↑ vascular volume</li>
<li>exacerbation of fluid accumulation</li>
</ul></li>
</ul>
→ potassium-sparing diuretic → Spirolactone is effective in this condition
</p>

<h1>iii.A.3-Nephrotic syndrome</h1>

<p>
→ after damage<br>
<ul style='padding-left: 30pt'>
<li>glomerural membranes allow plasma proteins to enter the glomerular ultrafiltrate</li>
<li>↓ collodial osmotic pressure</li>
<li>resulting in edema</li>
</ul>
→ low plasma volume<br>
<ul style='padding-left: 30pt'>
<li>stimulate aldosterone secretion [through renin-angiotensin-aldosterone system]</li>
<li>leads to retention of Na+ and fluid → which aggravating the edema</li>
</ul>
</p>

<h1>iii.A.4-Premanstrual edema</h1>

<p>
→ associated with mestruation<br>
<ul style='padding-left: 30pt'>
<li>imbalance in hormones
<ul>
<li>esterogen excess → loss of fluid in the extracellular space → diuretics [reduce edema]</li>
</ul></li>
</ul>
</p>

<h1>iii.B..-Nonedematous states</h1>

<br>

<h1>iii.B.1.-Hypertension</h1>

<p>
→ Thiazides have been widely used in the treatment of hypertension.<br>
<ul style='padding-left: 30pt'>
<li>ability not only to ↓ blood volume but also to dilate arterioles</li>
</ul>
</p>

<h1>iii.B.2.-Hypercalemia</h1>

<p>
→ loop diuretics are used<br>
<ul style='padding-left: 30pt'>
<li>promote calcium excretion</li>
</ul>
→ normal saline must also be unfused to maintain blood volume.
</p>

<h1>iii.B.3-Diabetes inspidus</h1>

<p>
→ when patients suffers from polyuria and polydipsia <br>
<ul style='padding-left: 30pt'>
<li>usually respond to thiazide diuretics.</li>
</ul>
→ ↓ plasma volume → drop in glomerular filtration rate and promoting the reabsorption of Na+ and water.
</p>

<h1>IV.THIAZIDES AND RELATED AGENTS</h1>

<p>
→ Sulfonamides derivatives<br>
<ul style='padding-left: 30pt'>
<li>related structure to carbonic anhydrase inhibitors</li>
</ul>
→ greater diuretic activity than <i>acetazolamide</i><br>
<ul style='padding-left: 30pt'>
<li>they act on the kidney by different mechanims</li>
</ul>
→ affect the distal tubule<br>
<ul style='padding-left: 30pt'>
<li>all have equal maxium diuretic effect
<ul>
<li>differing only in potency.</li>
</ul></li>
</ul>
→ called "celling diuretics"<br>
<ul style='padding-left: 30pt'>
<li>↑ the dose above normal 
<ul>
<li>does not promote a further diuretic response.</li>
</ul></li>
</ul>
→ like loop diuretics and thiazide actions partly depend on renal prostagladin syntheis
</p>

<h1>IV.A.Clorothiazide</h1>

<p>
→ first modern diuretic<br>
<ul style='padding-left: 30pt'>
<li>orally active</li>
<li>affecting the severe edema of cirrhosis and heart failure with min. side effects</li>
</ul>
</p>

<h1>Hydrochlorothiazide and Chlorothalidone</h1>

<p>
→ now used more commonly<br>
→ <i>Hydrochlorothiazide </i><br>
<ul style='padding-left: 30pt'>
<li>far less ability to inhibit carbonic anhydrase compared to <i>chlorothiazide.</i></li>
<li>it is also more potent.</li>
<li>required dose is considerably lower than that of <i>chlorothiazide</i></li>
</ul>
→ on the other hand<br>
<ul style='padding-left: 30pt'>
<li>efficacy is exactly the same </li>
</ul>
<i>[chlorthalidone,indapamide,metolazone reffered as thiazide-like diuretics because they contain sulfonamide residue in their chemical structures and their mechanism of aciton is similar]-[they are not truly thiazides]</i>
</p>

<h1>IV.A.1.-Mechanism of action</h1>

<p>
→ act mainly in the cortical region of the<br>
<ul style='padding-left: 30pt'>
<li>ascending loop of Henle </li>
<li>distal tubule
<ul>
<li>to ↓ reabsorption of Na+
<ul>
<li>by inhibition of a Na+/Cl- co-transporter of the luminal membrane of the tubules.</li>
</ul></li>
</ul></li>
</ul>
→ less effect in the proximal tube.<br>
<ul style='padding-left: 30pt'>
<li>↑ conc. of Na+ and Cl- in the tubular fluid,</li>
</ul>
→ acid-base balance is not usually affected.<br>
[<i>because the site of action of thiazides derivatives is on the luminal membrane ; with '↓ renal function , thiazide diuretics lose efficacy.]</i>
</p>

<h1>IV.A.2.-Actions</h1>

<p>
a.Increased excretion of Na+ and Cl-<br>
<ul style='padding-left: 30pt'>
<li>cause diuresis with ↑ Na+ and Cl- exrection  → excrection of avery hyperosmolar urine.</li>
</ul>
b.Loss of K+<br>
<ul style='padding-left: 30pt'>
<li>because thiazides ↑ the Na in the filtrate arriving at the distal tube	
<ul>
<li>more K+ is also exchanged for Na+
<ul>
<li>resulting in the continual loss of K+ from the body with prolonged use of drugs</li>
</ul></li>
</ul></li>
</ul>
c.Loss of  Mg+<br>
<ul style='padding-left: 30pt'>
<li>Mg deficiency requring supplementation which can occur with chronic use of thiazides diuretics
<ul>
<li>particulary in elderly patients</li>
</ul></li>
</ul>
d.Deacreased urinary calcium excretion<br>
<ul style='padding-left: 30pt'>
<li>↓ Ca+ content urine by promoting the reabsorption of Ca+</li>
</ul>
[the effects contrasts with the loop diuretic,which ↑ the Ca+ conc. of the urine.]<br>
e.Reduce peripheral vascular resistance<br>
<ul style='padding-left: 30pt'>
<li>initial reduction in blood pressure  → ↓ blood volume → ↓ cardiac output</li>
<li>continued hypotensive effect resulted from ↓ periphera; vascular resistance.</li>
</ul>
</p>

<h1>IV.A.3.-Therapeutic uses</h1>

<br>

<h1>iv.A.3.a.-Hypertension</h1>

<p>
→ mainstay of hypertention medicaiton<br>
→ ↓ systolic and diastolic blood pressure<br>
<ul style='padding-left: 30pt'>
<li>for mild/moderate hypertention</li>
</ul>
→ blood pressure stabilized at lower level and can be maintained by daily dose<br>
<ul style='padding-left: 30pt'>
<li>causing a low peripheral resistance without having a major diuretic effect.</li>
</ul>
</p>

<h1>iv.A.3.b.-Heart failure</h1>

<p>
→ loop diuretics<br>
<ul style='padding-left: 30pt'>
<li>choice of ↓ extracellular volume in heart failure</li>
</ul>
</p>

<h1>iv.A.3.c.-Hypercalciuria</h1>

<p>
→ treating idiopathic hypercalciuria<br>
<ul style='padding-left: 30pt'>
<li>inhibit urinary Ca+2 excrection</li>
</ul>
→ particular benifit in patients with calcium oxalate stones.
</p>

<h1>iv.A.4.-Pharmacokinetics</h1>

<p>
→ are effective orally<br>
→ 1 to 3 weeks to produce a stable reduction in blood pressure<br>
<ul style='padding-left: 30pt'>
<li>exhibit a  prolonged biologic half-life.</li>
</ul>
→ all thiazides secreted by the organic acid secretory syste of the kidney.
</p>

<h1>IV.5.Adverse effects</h1>

<p>
→ fluid and electrolyte balance
</p>

<h1>IV.5.a.potassium depletion</h1>

<p>
→ can predispose patients with digoxin treatment to ventricular arrythmias<br>
→ K+ can be supplemented by diet alone<br>
<ul style='padding-left: 30pt'>
<li>↑ intake of citrus frutis , bananas and prunes.</li>
</ul>
→ activation of renin-angiotensin-aldosterone system <br>
<ul style='padding-left: 30pt'>
<li>by ↓ in intravascular volume → K+ losses.</li>
</ul>
→ K+ deficiency can be overcome by<br>
<ul style='padding-left: 30pt'>
<li>spirolactone [which interferes with aldosteorne aciton]</li>
<li>or by admin. of triamterene or amiloride
<ul>
<li>act to retain K+</li>
</ul></li>
</ul>
→ low-sodium diet blunt the potassium depletion caused by thiazide diuretics
</p>

<h1>IV.5.b-hyponatremia</h1>

<p>
→may develop due to 	<br>
<ul style='padding-left: 30pt'>
<li>elevation of ADH as a result of hypovolemia</li>
<li>diminished diluting capactiy of the kidney and ↑ thirst.</li>
</ul>
→ limiting water intake and ↓ the dose of diuretic 
</p>

<h1>IV.5.c.-hyperuricemia</h1>

<p>
→ thiazides ↑ serum uric acid by ↓ the amount of acid excreted by the organic acid secretory system<br>
→ insoluble,uric acid deposits in the joints
</p>

<h1>IV.5.d.-volume depletion</h1>

<p>
→ orthostatic hypotention / light-headaeches
</p>

<h1>IV.5.e.hypercalcemia</h1>

<p>
→ inhibit the secretion of Ca2+ → elevated levels of Ca2+ in the blood
</p>

<h1>IV.5.f.hyperglycemia</h1>

<p>
→ due to impaired release of insulin and tissue uptake of glucose.
</p>

<h1>IV.5.g.hyperlipidemia</h1>

<p>
→ can cause 5-15% ↑ in serum cholesterol <br>
<ul style='padding-left: 30pt'>
<li>as well as ↑ serum low density lipoproteins.</li>
</ul>
→ lipid levels may return to normal with long-term therapy
</p>

<br>

<h1>B.THIAZIDE-LIKE analogs</h1>

<p>
→ lack the thiazide structure <br>
<ul style='padding-left: 30pt'>
<li>but like thiazides hae the unsubstituted sulfonamide group</li>
</ul>
</p>

<h1>Chlorthalidone</h1>

<p>
→ nonthiazide derivative<br>
→ pharmacologically like hydrochlorothiazide<br>
<ul style='padding-left: 30pt'>
<li>long duration of action </li>
<li>treat hypotention 	[once per day for this indication]</li>
</ul>
</p>

<h1>Metolazone</h1>

<p>
→ more potent than the thiazides<br>
→ caused Na+ excretion in advanced in renal failure
</p>

<h1>Indapamide</h1>

<p>
→ lipid-soluble <br>
<ul style='padding-left: 30pt'>
<li>non thiazide diuretic</li>
<li>long duration of action</li>
</ul>
→ antihypertensive action<br>
<ul style='padding-left: 30pt'>
<li>minimal diuretic effects</li>
</ul>
→ metabolized and excreted by the GIT and the kidneys.<br>
→ less likely to accumulate in patients with renal failure
</p>

<h1>V,LOOP OR HIGH-CELING DIURETICS</h1>

<p>
→ <i>Bumetanide, furosemide , torsemide , ethacrynic acid</i><br>
<ul style='padding-left: 30pt'>
<li>major action on the ascending limb of the loop of Henle.</li>
</ul>
→ highest efficacy in mobilizing Na+ and Cl- from the body.<br>
→ produce copius amount of urine<br>
→ Furosemide the most commonly used<br>
<ul style='padding-left: 30pt'>
<li>Ethacrynic acid has steeper dose-response curn than furosemide
<ul>
<li>shows greater side effects than those with other loop diuretics</li>
</ul></li>
</ul>
→ Bumetanide is much more  potent than furosemide [and it's use increases]
</p>

<h1>V.A.Bumetanide,furosemide,torsemide,ethacrynic acid.</h1>

<p>
1.MOA<br>
→ contransport of Na+/K+/2Cl in the luminal membane in the ascending limb of the loop of Henle.<br>
→ reabsorption of these ions is decreased<br>
→ most efficacious<br>
<ul style='padding-left: 30pt'>
<li>because of the ascending limb accounts for the reabsorption of 25 to 30 % of filtered <a href="./NaCl.html" title="NaCl" class="page">NaCl</a>
<ul>
<li>and downstreams sites are not able to compensate for this ↑ Na+ load.</li>
</ul></li>
</ul>
2.ACTIONS<br>
→ act promptly even among patients wh o have poor renal function<br>
→ have not repsond to thiazide or other diuretics<br>
[↑ Ca2+ content of urine, whereas thiazides ↓ Ca2+]<br>
[In patients with normal serum Ca2+ levels hypocalcemia does not reuslt <br>
<ul style='padding-left: 30pt'>
<li>because Ca2+ is reasorbed in the distal tubule.</li>
</ul>
→ ↓ renal vasular resistance and ↑ renal blood flow<br>
→ also ↑ prostaglandin synthesis<br>
<ul style='padding-left: 30pt'>
<li>NSAIDS[indomethacin] → interefere in prostaglandin synthesis can ↓ the diuretic action of these agents.</li>
</ul>
3.THERAPEUTIC USES<br>
→ ↓ the acute pulmonary edema of heart failure<br>
→ rapid onest of action when IV drugs are useful in emergency situation	<br>
<ul style='padding-left: 30pt'>
<li>such acute pulmonary edema</li>
</ul>
→ loops diuretics along with hydration useful in treating hypercalcemia<br>
<ul style='padding-left: 30pt'>
<li>cuz they stimulate Ca2+ excretion</li>
</ul>
→ also useful in treatment of hyperkalemia
</p>

<h1>V.A.1.-Pharmacokientics</h1>

<p>
→ orally or parenterally<br>
<ul style='padding-left: 30pt'>
<li>duration of action brief to 2 - 4 hours</li>
<li>they are secreted into urine</li>
</ul>
</p>

<h1>V.5.2-Adverse Effects</h1>

<p>
→ Ototoxicty <br>
<ul style='padding-left: 30pt'>
<li>most likely Ethacrynic acid</li>
</ul>
→ Hyperuricemia<br>
<ul style='padding-left: 30pt'>
<li>furosemide and ethacrynic acid comepete with uric acid for the renal and bilary secretory systems
<ul>
<li>blocking secretion in turn causing or exacerbating outy attacks</li>
</ul></li>
</ul>
→ Acute hypovolemia<br>
<ul style='padding-left: 30pt'>
<li>severe and rapid ↓ in blood volume</li>
<li>possibility of hypotention,shock,cardiac arrythmias.</li>
</ul>
→ Potassium depletion<br>
<ul style='padding-left: 30pt'>
<li>heavy load of Na+ preesnted to the collecting tubule → ↑ exchange of tubular Na+ for K+
<ul>
<li>inducing hypokalemia</li>
</ul>
</li>
<li>loss of K+ from cells in exchange to H+ leads to hypokalemic alkalosis.</li>
</ul>
→ Hypomagnesemia<br>
<ul style='padding-left: 30pt'>
<li>chronic usage of loop diuretics and low dietary intake of Mg+2 → hypomagnesemia</li>
</ul>
</p>
<h1>VI.POTASSIUM-SPARING DIURETICS</h1>

<p>
→ act in the collecting tubule to inhibit Na+<br>
<ul style='padding-left: 30pt'>
<li>reabsorption and K+ excretion</li>
</ul>
→ major treatment of hypertention<br>
<ul style='padding-left: 30pt'>
<li>most often in combo with thiazides.</li>
</ul>
→ close monitor of patients potassium levels.<br>
→ should be avoided in patients with renal dysfunction becauseu of the increased hyperkalemia.
</p>

<h1>VI.A.Adlosterone antagonist, Spirolactone and Eplerenone</h1>

<p>
1.MOA<br>
→ Spirolactone<br>
<ul style='padding-left: 30pt'>
<li>synthetic steroid that antagonize aldosterone at intracellular cytoplasmic receptors sites</li>
<li>spirolactone-receptor complex is inactive</li>
<li>prevent translocation of the receptor complex
<ul>
<li>into the nucleus of the target cell → cannot bind DNA</li>
</ul>
</li>
<li>failure to produce proteins [that normaly synthesized in response to aldosterone]
<ul>
<li>mediator proteins normally stimulate Na+/K+ exchange sites of the collecting tubules.</li>
</ul>
</li>
<li>lack of mediator proteins  prevent Na+ reabsorption and, therefor,K+and H+ secretion</li>
</ul>
2.ACTIONS<br>
→edematous staes,blood levels of aldosterone are high<br>
<ul style='padding-left: 30pt'>
<li>retention of Na</li>
</ul>
→ when spirolactone is given to a patient with elevated circulating levels of aldosterone<br>
<ul style='padding-left: 30pt'>
<li>drug antagonize the activity of the hormone → retention of K+ and excretion of Na+</li>
</ul>
→ in common with thiazides+loop diuretics,effects of spirolactone depends on renal prostagladins synthesis.<br>
→ Elperenone<br>
<ul style='padding-left: 30pt'>
<li>new aldosterone-receptor antagonist
<ul>
<li>actions comparable to those of spirolactone</li>
</ul>
</li>
<li>may have less endocrine effects than spirolactone.</li>
</ul>
3.THERAPEUTIC USE<br>
A.DIURETIC<br>
→ spirolactone has low efficay in mobilizng Na+ from the body in comparison with other drugs<br>
<ul style='padding-left: 30pt'>
<li>causing retention of K+
<ul>
<li>because of this action is often given with conjuctin with thiazides and loop diuretics</li>
<li>drug of choise in patients with hepatic cirrhosis.</li>
</ul></li>
</ul>
B.SECONDARY HYPERALDOSTERONISM<br>
→ Spirolactone is the only potassium-sparing diuretic that is routinely used alone to induce a net negative salt balance<br>
C.HEART FAILURE<br>
→ prevents remodeling that occurs as compensation for the progressive failure of the heart.<br>
→ ↓ mortality associated with herat failure.
</p>

<h1>IV.Pharmacokientics</h1>

<p>
→ spirolactone is <br>
<ul style='padding-left: 30pt'>
<li>completely absorbed orally </li>
<li>strongly bound to proteins</li>
</ul>
→ rapidly metabolized to canrenone<br>
<ul style='padding-left: 30pt'>
<li>which has mineralcorticoid-blocking activity.</li>
<li>induce hepatic cythochrome P450</li>
</ul>
</p>

<h1>IV.Adverse effects</h1>

<p>
→ cause gastic upsets<br>
→ peptic ulcers<br>
→ chemically resemble sex steroid spirolactone may act at receptors in the other organs<br>
<ul style='padding-left: 30pt'>
<li>do induce gynecomastia [in male patients</li>
<li>should not be given for a chronic use</li>
</ul>
→ in mild edematous states <br>
<ul style='padding-left: 30pt'>
<li>few days at a time</li>
</ul>
→ hyperkalemia,nausea,lethargy and metnal confusion can occur.
</p>

<h1>Triamterene and amiloride</h1>

<p>
→ Triamterene and amiloride<br>
<ul style='padding-left: 30pt'>
<li>block Na+ transport channels
<ul>
<li>↓ in Na+/K+ exchange site in the collecting tubule 
<ul>
<li>does not depends in the presence of aldosteorne</li>
</ul></li>
</ul>
</li>
<li>have diuretic activity even in patients with Adisson disease</li>
</ul>
→ like spirolactone is not efficacius diuretic<br>
→ both are commonly used in combination with other diuretics<br>
<ul style='padding-left: 30pt'>
<li>potassium-sparing properties</li>
</ul>
→ prevent loss of K+ that occurs with thiazides and furosemide.<br>
→ side effetcts<br>
<ul style='padding-left: 30pt'>
<li>leg cramps and possiblity of ↑ blood urea nitrogen as wella s uric acid and K+ retention.</li>
</ul>
</p>

<h1>VII. CARBONIC ANHYDRASE INHIBITOR</h1>

<p>
→ <i>Acetozolamide</i><br>
<ul style='padding-left: 30pt'>
<li>inhibits the enzyme carbonic anhydrase 
<ul>
<li>in the proximal tubular epithelial cells</li>
<li>much less efficacious than the thiazides or loops diuretic</li>
</ul></li>
</ul>
1.MOA<br>
→ inhibits carbonic anhydrase located intracellularly (cytoplasm)<br>
<ul style='padding-left: 30pt'>
<li>apical membrane of the proximal tubular epithelium
<ul>
<li>catalyze reaction of CO2 + H2O → H2CO3 [which ionize to H+ and HCO3]-[bicarbonate]
<ul>
<li>↓ ability to exchange Na+ and H+ in the presence of acetazolamide results in mild diuresis</li>
</ul></li>
</ul>
</li>
<li>Aditionally HCO3 is retained in the lumen → ↑ urinary pH</li>
<li>causes hyperchoremic metabolic acidosis and ↓ diuretic efficay</li>
</ul>
2.THEREPEUTIC USES<br>
a.Treatment of glaucoma<br>
→ ↓ the elevated intraocular pressure of open-angle glaucoma<br>
→ ↓ the production of aqueous humor<br>
<ul style='padding-left: 30pt'>
<li>blocking carbonic anhydrase
<ul>
<li>in the ciliary body of the eye</li>
</ul>
</li>
<li>should not be used for an acute attack</li>
</ul>
→ <i>Dorzolamide and brinzolaimde</i><br>
<ul style='padding-left: 30pt'>
<li>not causing any systemic effects</li>
</ul>
b.Mountain sickness<br>
→ prophylaxis of acute mountain sickness<br>
<ul style='padding-left: 30pt'>
<li>given nightly for 5 days
<ul>
<li>ascent prevents the weakness, breathlessness,dizniess,nausea.</li>
</ul></li>
</ul>
3.PHARMACOKINETICS<br>
→ given orally 4xdays<br>
→ secreted by the proximal tubule<br>
4.ADVERSE EFFECTS<br>
→ metabolic acidosis (mild)<br>
→ potassium depletion<br>
→ renal stone formation<br>
→ drowsiness<br>
→ paresthesia may occur.<br>
→ should be avoided in patients with hepatic cirrhosis<br>
<ul style='padding-left: 30pt'>
<li>↓ excretion of NH4+</li>
</ul>
</p>

<h1>VIII.OSMOTIC DIURETICS</h1>

<p>
→ hydrophilic chemical substances<br>
<ul style='padding-left: 30pt'>
<li>filtered through the glomerulus
<ul>
<li><i>Mannitol and Urea</i>
<ul>
<li>result in some degrees of diuresis</li>
</ul></li>
</ul>
</li>
<li>ability to carry water with them into the tubular fluid.</li>
<li>if the sub that is filtered subsequently undergoes 
<ul>
<li>little or no absorption</li>
</ul>
</li>
<li>then the filtered substance will cause ↑ in urinary output.</li>
<li>only small amount of additional salt may also be excreted</li>
</ul>
→ osmotic diuretics are used to effect ↑ water excretion rather than Na+ excretion<br>
<ul style='padding-left: 30pt'>
<li>they are not useful for treatining condintion in which Na+ retention occurs</li>
</ul>
→ used to maintain urinary flow → acute toxic ingenstion of substances capable of producin acute renal failure<br>
→ mainstray in the treatment of <br>
<ul style='padding-left: 30pt'>
<li>↑ intracranial pressure or acute renal failure 
<ul>
<li>due to sock , drug toxicites and trauma</li>
</ul>
</li>
<li>maintain urine flow preserves long term kideny function </li>
</ul>
[mannitol is not absorbed when given orally and hsould only be given IV]<br>
→ adverse effects include<br>
<ul style='padding-left: 30pt'>
<li>extracellular water expansion  and dehydration</li>
<li>expansion of extracellular water results becaues the presence of manniotr in the extrecellular fluid.</li>
<li>deyhdration may occur if water is not replaced adequately</li>
</ul>
</p>


	</div>

	<br />

	<div class='page-footer'>

			<b>Attachments:</b>
			<table>

			<tr><td><a href='./Pharmacology/pasted_image.png'>pasted_image.png</a></td><td>&nbsp;</td><td>179kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image001.png'>pasted_image001.png</a></td><td>&nbsp;</td><td>133kb</td></tr>

			</table>
	</div>

	

</div>

</body>
</html>
